{
  "personality": null,
  "timestamp": "2026-02-02T05:34:08.296336",
  "category": "Health",
  "news_summary": "Recent scientific breakthroughs are advancing understanding of aging, brain function, consciousness, and autism through innovative research on gut bacteria, memory processes, and stem cell models.",
  "news_summary_fr": "Les récentes avancées scientifiques permettent de mieux comprendre le vieillissement, le fonctionnement du cerveau, la conscience et l'autisme grâce à des recherches innovantes sur les bactéries intestinales, les processus mémoriels et les modèles de cellules souches.",
  "news_summary_es": "Los recientes avances científicos están mejorando la comprensión del envejecimiento, la función cerebral, la conciencia y el autismo a través de investigaciones innovadoras sobre las bacterias intestinales, los procesos de memoria y los modelos de células madre.",
  "articles": [
    {
      "title": "Scientists discover how to turn gut bacteria into anti-aging factories",
      "summary": "Researchers found that small doses of an antibiotic can coax gut bacteria into producing a life-extending compound. In worms, this led to longer lifespans, while mice showed healthier cholesterol and insulin changes. Because the drug stays in the gut, it avoids toxic side effects. The study points to a new way of promoting health by targeting microbes rather than the body itself.",
      "content": "Researchers have discovered a way to coax the bacteria living in animals' digestive systems into acting like miniature factories that produce compounds linked to longer life. The findings point to a potential new approach for developing drugs that work by influencing gut microbes rather than directly targeting the body.\n\nThe work was led by Janelia Senior Group Leader Meng Wang, whose lab focuses on understanding the biology of aging. Her team wanted to find a practical way to translate their earlier discoveries about longevity-related compounds into something that could eventually be useful beyond the laboratory.\n\nUsing the Gut Microbiota to Produce Beneficial Compounds\n\nThe researchers explored whether they could prompt the body's gut microbiota (a collection of bacteria in the gut that produces many different compounds) to make substances that support health and longevity. They focused on colanic acid, a compound naturally produced by gut bacteria that had already been shown to extend lifespan in roundworms and fruit flies.\n\nIn their latest experiments, Wang's team found that gut bacteria produced much higher levels of colanic acids when exposed to low doses of the antibiotic cephaloridine. Roundworms given cephaloridine lived longer, linking the increase in this bacterial compound to improved longevity.\n\nThe researchers then tested the approach in mice. Low doses of cephaloridine activated gene expression in gut bacteria involved in making colanic acids. This led to noticeable shifts in age-related metabolism, including higher levels of good cholesterol and lower levels of bad cholesterol in male mice, along with reduced insulin levels in female mice.\n\nWhy the Approach Avoids Side Effects\n\nCephaloridine has an important advantage. When taken orally, it is not absorbed into the bloodstream. That means it can influence the gut microbiome without affecting the rest of the body, helping to avoid toxicity and unwanted side effects.\n\nAccording to the researchers, the results highlight a promising strategy for promoting longevity using drugs that act on bacteria rather than human cells. They suggest this work could reshape how future medicines are designed, shifting the focus toward compounds that guide the microbiota to produce health-supporting molecules for their hosts.",
      "url": "https://www.sciencedaily.com/releases/2026/01/260131085024.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2026-02-01",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant scientific breakthrough where researchers discovered a method to extend lifespan and improve metabolic health by manipulating gut bacteria to produce beneficial compounds. This approach has broad implications for aging and health, with demonstrated positive effects in animal models and a novel mechanism that avoids toxic side effects, indicating a meaningful advancement in health science.",
      "category": "Health",
      "personality_title": "Scientists use gut bacteria to create compounds that may extend life",
      "personality_presentation": "**Context** – Scientists have been studying how certain compounds can help animals live longer. They wanted to find a way to produce these helpful substances inside the body without harmful side effects.\n\n**What happened** – A research team led by Meng Wang discovered that giving small doses of an antibiotic called cephaloridine to animals can make the bacteria in their guts produce more of a special compound called colanic acid. In experiments, roundworms lived longer, and mice showed healthier cholesterol and insulin levels after this treatment.\n\n**Impact** – This discovery is important because the antibiotic stays only in the gut and does not enter the bloodstream, which means it can help the bacteria make good compounds without causing harm to the rest of the body. It suggests a new way to improve health by working with gut bacteria instead of directly targeting the body’s cells.\n\n**What's next step** – Researchers hope to explore this method further to develop new medicines that help people live healthier lives by encouraging their gut bacteria to produce beneficial substances safely.\n\n**One-sentence takeaway** – Scientists found that low doses of an antibiotic can turn gut bacteria into factories that produce compounds linked to longer life and better health.",
      "personality_title_fr": "Des scientifiques utilisent les bactéries intestinales pour créer des composés qui pourraient prolonger la vie",
      "personality_presentation_fr": "**Contexte** – Les scientifiques étudient comment certains composés peuvent aider les animaux à vivre plus longtemps. Ils cherchaient un moyen de produire ces substances utiles dans le corps sans effets secondaires dangereux.\n\n**Ce qui s'est passé** – Une équipe dirigée par Meng Wang a découvert que donner de faibles doses d'un antibiotique appelé céphaloridine aux animaux peut faire produire plus d'un composé spécial nommé acide colanique par les bactéries de leur intestin. Dans les expériences, les vers ont vécu plus longtemps, et les souris ont montré des niveaux de cholestérol et d'insuline plus sains après ce traitement.\n\n**Impact** – Cette découverte est importante car l'antibiotique reste uniquement dans l'intestin et ne pénètre pas dans le sang, ce qui signifie qu'il peut aider les bactéries à fabriquer des composés bénéfiques sans nuire au reste du corps. Cela suggère une nouvelle façon d'améliorer la santé en travaillant avec les bactéries intestinales plutôt qu'en ciblant directement les cellules du corps.\n\n**Prochaine étape** – Les chercheurs espèrent approfondir cette méthode pour développer de nouveaux médicaments qui aideront les personnes à vivre plus sainement en encourageant leurs bactéries intestinales à produire des substances bénéfiques en toute sécurité.\n\n**Message en une phrase** – Des scientifiques ont découvert que de faibles doses d'un antibiotique peuvent transformer les bactéries intestinales en usines produisant des composés liés à une vie plus longue et une meilleure santé.",
      "personality_title_es": "Científicos usan bacterias intestinales para crear compuestos que podrían extender la vida",
      "personality_presentation_es": "**Contexto** – Los científicos han estado estudiando cómo ciertos compuestos pueden ayudar a los animales a vivir más tiempo. Querían encontrar una manera de producir estas sustancias útiles dentro del cuerpo sin efectos secundarios dañinos.\n\n**Qué pasó** – Un equipo de investigación dirigido por Meng Wang descubrió que al dar pequeñas dosis de un antibiótico llamado cefaloridina a los animales, las bacterias en sus intestinos producían más de un compuesto especial llamado ácido colánico. En los experimentos, los gusanos vivieron más tiempo y los ratones mostraron niveles más saludables de colesterol e insulina tras el tratamiento.\n\n**Impacto** – Este descubrimiento es importante porque el antibiótico permanece solo en el intestino y no entra en el torrente sanguíneo, lo que significa que puede ayudar a las bacterias a fabricar compuestos beneficiosos sin dañar el resto del cuerpo. Esto sugiere una nueva forma de mejorar la salud trabajando con las bacterias intestinales en lugar de atacar directamente las células del cuerpo.\n\n**Próximo paso** – Los investigadores esperan explorar más este método para desarrollar nuevos medicamentos que ayuden a las personas a vivir vidas más saludables alentando a sus bacterias intestinales a producir sustancias beneficiosas de forma segura.\n\n**Frase clave** – Científicos descubrieron que dosis bajas de un antibiótico pueden convertir las bacterias intestinales en fábricas que producen compuestos relacionados con una vida más larga y mejor salud.",
      "image_url": "public/images/news_image_Scientists-discover-how-to-turn-gut-bacteria-into-.png",
      "image_prompt": "A warm, detailed painting of a stylized animal digestive tract shaped like a glowing factory, with friendly, colorful bacteria inside producing bright, shimmering molecular structures labeled as longevity compounds, surrounded by soft natural hues and subtle representations of healthy metabolism such as balanced cholesterol and insulin symbols depicted abstractly through gentle swirling patterns."
    },
    {
      "title": "Alzheimer’s scrambles memories while the brain rests",
      "summary": "When the brain rests, it usually replays recent experiences to strengthen memory. Scientists found that in Alzheimer’s-like mice, this replay still occurs — but the signals are jumbled and poorly coordinated. As a result, memory-supporting brain cells lose their stability, and the animals struggle to remember where they’ve been.",
      "content": "New research suggests that memory problems in Alzheimer's disease may be linked to a failure in how the brain replays recent experiences while at rest. The study, conducted in mice by scientists at University College London (UCL), points to a disrupted brain process that normally helps strengthen and preserve memories.\n\nThe researchers say their findings, published in Current Biology, could support the development of future drug treatments that target this malfunctioning process. The work may also help guide the creation of new tools for detecting Alzheimer's earlier than is currently possible.\n\nUnderstanding How Alzheimer's Disrupts Brain Cells\n\nCo-lead author Dr Sarah Shipley (UCL Cell & Developmental Biology) explained that Alzheimer's disease is driven by the accumulation of damaging proteins and plaques in the brain. These changes lead to symptoms such as memory loss and difficulty navigating familiar environments, but the precise ways these plaques interfere with normal brain activity are still unclear.\n\n\"Alzheimer's disease is caused by the build-up of harmful proteins and plaques in the brain, leading to symptoms such as memory loss and impaired navigation -- but it's not well understood exactly how these plaques disrupt normal brain processes.\n\n\"We wanted to understand how the function of brain cells changes as the disease develops, to identify what's driving these symptoms.\n\n\"When we rest, our brains normally replay recent experiences -- this is thought to be key to how memories are formed and maintained. We found this replay process is disrupted in mice engineered to develop the amyloid plaques characteristic of Alzheimer's, and this disruption is associated with how badly animals perform on memory tasks.\"\n\nHow the Brain Replays Memories\n\nThis replay activity takes place in the hippocampus, a brain region essential for learning and memory. During rest, specific neurons known as place cells activate in rapid sequences that mirror recent experiences.\n\nPlace cells, discovered by Nobel prize-winning UCL neuroscientist Professor John O'Keefe, are neurons (brain cells) that correspond to particular locations. As a person or animal moves through a space, different place cells fire in a specific order. Later, during rest, those same cells typically reactivate in the same sequence, helping the brain store the experience as a memory.\n\nTracking Brain Activity During Memory Tasks\n\nTo study this process, researchers tested how mice performed in a simple maze while recording brain activity at the same time. Using specialized electrodes, they were able to monitor roughly 100 individual place cells simultaneously as the animals explored and then rested.\n\nThis approach allowed the team to compare normal brain replay patterns with those seen in mice that had developed amyloid pathology associated with Alzheimer's disease.\n\nDisorganized Replay and Fading Memory Signals\n\nIn mice with amyloid plaques, memory replay looked very different. Replay events occurred just as often as they did in healthy mice, but the underlying patterns were no longer organized. Instead of reinforcing memories, the coordinated activity of place cells became scrambled.\n\nThe researchers also observed that place cells in affected mice grew less stable over time. Individual neurons stopped reliably representing the same locations, especially after rest periods, which are normally when replay should strengthen memory signals.\n\nMemory Performance Declines in Affected Mice\n\nThese changes had clear behavioral effects. Mice with disrupted replay performed worse in the maze, frequently revisiting paths they had already explored and appearing unable to remember where they had been.\n\nCo-lead author Professor Caswell Barry (UCL Cell & Developmental Biology) said the study reveals a failure in memory consolidation that can be seen at the level of single neurons.\n\n\"We've uncovered a breakdown in how the brain consolidates memories, visible at the level of individual neurons. What's striking is that replay events still occur -- but they've lost their normal structure. It's not that the brain stops trying to consolidate memories; the process itself has gone wrong.\"\n\nImplications for Early Detection and Treatment\n\nProfessor Barry added that these findings may help researchers identify Alzheimer's earlier or develop treatments that focus on restoring normal replay activity.\n\n\"We hope our findings could help develop tests to detect Alzheimer's early, before extensive damage has occurred, or lead to new treatments targeting this replay process. We're now investigating whether we can manipulate replay through the neurotransmitter acetylcholine, which is already targeted by drugs used to treat Alzheimer's symptoms. By understanding the mechanism better, we hope to make such treatments more effective.\"\n\nThe research was carried out by scientists in the UCL Faculties of Life Sciences and Brain Sciences, with support from the Cambridge Trust, Wellcome, and the Masonic Charitable Foundation.",
      "url": "https://www.sciencedaily.com/releases/2026/02/260201062459.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2026-02-01",
      "sentiment_score": 0.85,
      "reasoning": "The article reports a significant scientific discovery about how Alzheimer's disease disrupts memory consolidation at the neuronal level. This breakthrough enhances understanding of the disease mechanism, which could lead to earlier detection and improved treatments benefiting a broad population affected by Alzheimer's. The study is detailed and focused on a single important topic with clear real-world implications.",
      "category": "Health",
      "personality_title": "Scientists uncover how Alzheimer's disrupts memory replay in the brain",
      "personality_presentation": "**Context** – Alzheimer's disease causes memory loss and trouble remembering places. Scientists know this is linked to harmful proteins building up in the brain, but they don’t fully understand how these proteins affect memory processes.\n\n**What happened** – Researchers at University College London studied mice designed to develop Alzheimer's-like brain changes. They recorded brain activity while mice explored a maze and then rested. Normally, during rest, brain cells called place cells replay recent experiences to help form memories. In the mice with Alzheimer's, this replay still happened but was disorganized and scrambled.\n\n**Impact** – The scrambled replay meant the place cells became less stable and stopped accurately representing locations. As a result, the mice had trouble remembering where they had been, showing worse maze performance. This discovery shows exactly how memory problems arise at the level of individual brain cells.\n\n**What's next step** – The researchers want to explore if they can fix this disorganized replay using drugs that affect brain chemicals like acetylcholine. This could lead to better treatments and ways to detect Alzheimer’s earlier, before severe memory loss happens.\n\n**One-sentence takeaway** – Scientists found that Alzheimer's scrambles memory replay in the brain, causing memory cells to lose stability and making it harder to remember places.",
      "personality_title_fr": "Des scientifiques découvrent comment Alzheimer perturbe la relecture des souvenirs dans le cerveau",
      "personality_presentation_fr": "**Contexte** – La maladie d'Alzheimer provoque une perte de mémoire et des difficultés à se souvenir des lieux. On sait que cela est lié à l'accumulation de protéines nocives dans le cerveau, mais on ne comprend pas encore complètement comment ces protéines affectent les processus de la mémoire.\n\n**Ce qui s’est passé** – Des chercheurs du University College London ont étudié des souris conçues pour développer des changements cérébraux similaires à ceux d'Alzheimer. Ils ont enregistré l'activité cérébrale pendant que les souris exploraient un labyrinthe puis se reposaient. Normalement, au repos, des cellules cérébrales appelées cellules de lieu rejouent les expériences récentes pour aider à former les souvenirs. Chez les souris atteintes d'Alzheimer, cette relecture avait lieu mais était désorganisée et brouillée.\n\n**Impact** – Cette relecture désordonnée a rendu les cellules de lieu moins stables, cessant de représenter correctement les endroits. En conséquence, les souris avaient du mal à se souvenir où elles étaient passées, montrant une moins bonne performance dans le labyrinthe. Cette découverte montre précisément comment les problèmes de mémoire apparaissent au niveau des cellules cérébrales.\n\n**Prochaine étape** – Les chercheurs veulent voir s'ils peuvent réparer cette relecture désorganisée en utilisant des médicaments qui agissent sur des substances chimiques du cerveau comme l’acétylcholine. Cela pourrait mener à de meilleurs traitements et à une détection plus précoce de la maladie d'Alzheimer.\n\n**Résumé en une phrase** – Les scientifiques ont découvert qu'Alzheimer brouille la relecture des souvenirs dans le cerveau, ce qui fait perdre leur stabilité aux cellules de mémoire et complique le souvenir des lieux.",
      "personality_title_es": "Científicos descubren cómo el Alzheimer altera la repetición de recuerdos en el cerebro",
      "personality_presentation_es": "**Contexto** – La enfermedad de Alzheimer causa pérdida de memoria y dificultades para recordar lugares. Se sabe que esto está relacionado con la acumulación de proteínas dañinas en el cerebro, pero no se entiende completamente cómo estas proteínas afectan los procesos de la memoria.\n\n**Qué pasó** – Investigadores del University College London estudiaron ratones diseñados para desarrollar cambios cerebrales similares a los del Alzheimer. Registraron la actividad cerebral mientras los ratones exploraban un laberinto y luego descansaban. Normalmente, durante el descanso, células cerebrales llamadas células de lugar repiten experiencias recientes para ayudar a formar recuerdos. En los ratones con Alzheimer, esta repetición ocurrió pero estaba desorganizada y confusa.\n\n**Impacto** – La repetición desordenada hizo que las células de lugar fueran menos estables y dejaran de representar correctamente las ubicaciones. Como resultado, los ratones tuvieron problemas para recordar dónde habían estado, mostrando peor rendimiento en el laberinto. Este descubrimiento muestra cómo surgen los problemas de memoria a nivel de las células cerebrales.\n\n**Próximo paso** – Los investigadores quieren investigar si pueden corregir esta repetición desorganizada usando medicamentos que afectan químicos cerebrales como la acetilcolina. Esto podría llevar a mejores tratamientos y formas de detectar el Alzheimer antes de que ocurra una pérdida severa de memoria.\n\n**Conclusión en una frase** – Los científicos encontraron que el Alzheimer desordena la repetición de recuerdos en el cerebro, haciendo que las células de memoria pierdan estabilidad y dificultando recordar lugares.",
      "image_url": "public/images/news_image_Alzheimers-scrambles-memories-while-the-brain-rest.png",
      "image_prompt": "A detailed, warm-toned painting of a softly glowing mouse navigating a gently winding maze made of interconnected neuron-like pathways, with delicate, shimmering sequences of light pulses flowing through a stylized hippocampus-shaped structure above, illustrating disrupted yet persistent memory replay in the brain."
    },
    {
      "title": "“Existential risk” – Why scientists are racing to define consciousness",
      "summary": "Scientists warn that rapid advances in AI and neurotechnology are outpacing our understanding of consciousness, creating serious ethical risks. New research argues that developing scientific tests for awareness could transform medicine, animal welfare, law, and AI development. But identifying consciousness in machines, brain organoids, or patients could also force society to rethink responsibility, rights, and moral boundaries. The question of what it means to be conscious has never been more urgent—or more unsettling.",
      "content": "As artificial intelligence continues to advance and ethical concerns grow alongside it, scientists say the need to understand consciousness has reached a critical point.\n\nIn a new review published in Frontiers in Science, researchers warn that progress in AI and neurotechnology is moving faster than scientific understanding of consciousness. This gap, they argue, could lead to serious ethical problems if it is not addressed.\n\nThe authors say explaining how consciousness emerges is now an urgent scientific and moral priority. A clearer understanding could eventually make it possible to develop scientific methods for detecting consciousness. That breakthrough would have far-reaching consequences for AI development, prenatal policy, animal welfare, medicine, mental health care, law, and emerging technologies such as brain-computer interfaces.\n\n\"Consciousness science is no longer a purely philosophical pursuit. It has real implications for every facet of society -- and for understanding what it means to be human,\" said lead author Prof Axel Cleeremans from Université Libre de Bruxelles. \"Understanding consciousness is one of the most substantial challenges of 21st-century science -- and it's now urgent due to advances in AI and other technologies.\n\n\"If we become able to create consciousness -- even accidentally -- it would raise immense ethical challenges and even existential risk,\" added Cleeremans, a European Research Council (ERC) grantee.\n\nThe Challenge of Defining Sentience\n\nConsciousness, commonly described as awareness of both the world around us and ourselves, remains one of science's most difficult puzzles. Despite decades of research, scientists still lack agreement on how subjective experience emerges from biological processes.\n\nResearchers have identified brain regions and neural activity linked to conscious experience, but major disagreements remain. Scientists continue to debate which brain systems are truly necessary for consciousness and how they interact to produce awareness. Some researchers even question whether this approach captures the problem correctly.\n\nThe new review examines the current state of consciousness science, future directions for the field, and the possible consequences if humans succeed in fully explaining or even creating consciousness. This includes the possibility of consciousness emerging in machines or in lab-grown brain-like systems known as \"brain organoids.\"\n\nTesting for Consciousness\n\nThe authors argue that developing evidence-based tests for consciousness could transform how awareness is identified across many contexts. Such tools could help detect consciousness in patients with brain injuries or dementia and determine when awareness arises in fetuses, animals, brain organoids, or even AI systems.\n\nWhile this would represent a major scientific advance, the researchers caution that it would also create difficult ethical and legal questions. Determining that a system is conscious would force society to reconsider how that system should be treated.\n\n\"Progress in consciousness science will reshape how we see ourselves and our relationship to both artificial intelligence and the natural world,\" said co-author Prof Anil Seth from the University of Sussex and ERC grantee. \"The question of consciousness is ancient -- but it's never been more urgent than now.\"\n\nMedical, Ethical, and Legal Implications\n\nA deeper understanding of consciousness could have wide-ranging effects across society.\n\nIn medicine, it could improve care for patients who are unresponsive and assumed to be unconscious. Measurements inspired by integrated information theory and global workspace theory[1] have already detected signs of awareness in some individuals diagnosed with unresponsive wakefulness syndrome. Further progress could refine these tools to better assess consciousness in coma, advanced dementia, and anesthesia, and influence treatment decisions and end-of-life care.\n\nMental health treatment could also benefit. Understanding the biological basis of subjective experience may help researchers develop better therapies for conditions such as depression, anxiety, and schizophrenia by narrowing the gap between animal studies and human emotional experience.\n\nGreater insight into consciousness could reshape how humans think about their moral responsibilities toward animals. Identifying which animals and systems are sentient could influence animal research practices, farming, food consumption, and conservation strategies. \"Understanding the nature of consciousness in particular animals would transform how we treat them and emerging biological systems that are being synthetically generated by scientists,\" said co-author Prof Liad Mudrik from Tel Aviv University and ERC grantee.\n\nRethinking Responsibility and Technology\n\nConsciousness research could also affect how the legal system understands responsibility. New findings may challenge traditional legal concepts such as mens rea, the \"guilty mind\" required to establish intent. As neuroscience reveals how much behavior arises from unconscious processes, courts may need to reconsider where responsibility begins and ends.\n\nAt the same time, advances in AI, brain organoids, and brain-computer interfaces raise the possibility of creating or altering awareness beyond natural biological limits. While some researchers believe consciousness might arise through computation alone, others argue that biological factors play an essential role. \"Even if 'conscious AI' is impossible using standard digital computers, AI that gives the impression of being conscious raises many societal and ethical challenges,\" said Seth.\n\nA Call for Coordinated Research\n\nThe authors emphasize the need for a coordinated, evidence-based approach to studying consciousness. One proposed strategy involves adversarial collaborations, in which competing theories are tested against each other through experiments designed jointly by their supporters. \"We need more team science to break theoretical silos and overcome existing biases and assumptions,\" said Mudrik. \"This step has the potential to move the field forward.\"\n\nThe researchers also argue that scientific work should place greater emphasis on phenomenology (what consciousness feels like) alongside studies of function (what consciousness does).\n\n\"Cooperative efforts are essential to make progress -- and to ensure society is prepared for the ethical, medical, and technological consequences of understanding, and perhaps creating, consciousness,\" said Cleeremans.\n\nNotes",
      "url": "https://www.sciencedaily.com/releases/2026/01/260131084626.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2026-02-01",
      "sentiment_score": 0.85,
      "reasoning": "The article highlights a significant scientific and ethical advancement in understanding consciousness, which has broad implications for medicine, mental health, animal welfare, law, and AI development. It presents a substantial, focused discussion on the potential to develop scientific tests for consciousness, promising transformative benefits for patient care, mental health treatment, and ethical considerations across society. The story emphasizes coordinated research efforts to address urgent challenges posed by rapid technological advances, making it an inspiring and hopeful development with wide societal impact.",
      "category": "Health",
      "personality_title": "Scientists race to understand consciousness amid AI breakthroughs",
      "personality_presentation": "**Context** – Advances in artificial intelligence (AI) and brain technology are happening very quickly. Scientists worry that we don’t yet fully understand consciousness, which means being aware of ourselves and the world around us. This lack of understanding could cause serious ethical problems as technology develops.\n\n**What happened** – Researchers published a new review warning that science is falling behind technology in explaining consciousness. They say it’s urgent to find ways to test if something is truly conscious. This could help doctors know if patients are aware, improve animal welfare, guide AI development, and change laws about responsibility and rights. The study points out that consciousness might even appear in machines or lab-grown brain tissues.\n\n**Impact** – Developing scientific tests for consciousness could change many areas of life. For example, doctors could better treat patients who seem unconscious, and mental health treatments could improve by understanding how feelings arise. It might also change how society treats animals and AI systems, raising new ethical questions. Legal ideas about responsibility could shift if we learn more about how consciousness works.\n\n**What's next step** – Scientists want to work together more closely, testing different ideas about consciousness through shared experiments. This teamwork can help overcome disagreements and speed up progress. They also want to study what consciousness feels like, not just how it works, to prepare society for the challenges of recognizing or even creating consciousness.\n\n**One-sentence takeaway** – Understanding and testing consciousness is becoming urgent as AI and brain technologies advance, with big effects expected in medicine, ethics, law, and technology.",
      "personality_title_fr": "Les scientifiques se précipitent pour comprendre la conscience face aux avancées de l’IA",
      "personality_presentation_fr": "**Contexte** – Les progrès rapides de l’intelligence artificielle (IA) et des technologies cérébrales inquiètent les scientifiques, car la conscience, c’est-à-dire la prise de conscience de soi et du monde, reste mal comprise. Ce manque de compréhension pourrait poser de graves problèmes éthiques.\n\n**Ce qui s’est passé** – Des chercheurs ont publié une revue alertant que la science accuse un retard face à la technologie pour expliquer la conscience. Ils soulignent l’urgence de développer des tests pour détecter la conscience. Cela aiderait les médecins à mieux soigner les patients, améliorerait le bien-être animal, guiderait le développement de l’IA et pourrait modifier les lois sur la responsabilité et les droits. La conscience pourrait même apparaître dans des machines ou des tissus cérébraux cultivés en laboratoire.\n\n**Impact** – Créer des tests scientifiques de la conscience pourrait transformer de nombreux domaines. Par exemple, les médecins pourraient mieux évaluer les patients apparemment inconscients, et les traitements de santé mentale pourraient progresser en comprenant mieux les émotions. Cela pourrait aussi changer la manière dont la société traite les animaux et les systèmes d’IA, soulevant de nouvelles questions éthiques. Les idées juridiques sur la responsabilité pourraient évoluer.\n\n**Prochaine étape** – Les scientifiques souhaitent collaborer davantage en testant ensemble différentes théories sur la conscience. Ce travail d’équipe aidera à dépasser les désaccords et accélérer les découvertes. Ils veulent aussi étudier ce que ressent la conscience, pas seulement comment elle fonctionne, pour préparer la société aux défis liés à la reconnaissance ou à la création de la conscience.\n\n**Conclusion en une phrase** – Comprendre et tester la conscience devient urgent avec les progrès de l’IA et des technologies cérébrales, avec de grandes répercussions attendues en médecine, éthique, droit et technologie.",
      "personality_title_es": "Científicos aceleran la comprensión de la conciencia ante avances en IA",
      "personality_presentation_es": "**Contexto** – Los rápidos avances en inteligencia artificial (IA) y tecnologías cerebrales preocupan a científicos porque la conciencia, que es la capacidad de darse cuenta de uno mismo y del mundo, aún no se entiende bien. Esta falta de comprensión podría causar serios problemas éticos.\n\n**Qué pasó** – Investigadores publicaron una revisión que alerta que la ciencia va detrás de la tecnología para explicar la conciencia. Destacan la urgencia de crear pruebas para detectar la conciencia. Esto ayudaría a los médicos a tratar mejor a los pacientes, mejoraría el bienestar animal, guiaría el desarrollo de la IA y podría cambiar las leyes sobre responsabilidad y derechos. La conciencia incluso podría surgir en máquinas o tejidos cerebrales cultivados en laboratorio.\n\n**Impacto** – Desarrollar pruebas científicas para la conciencia podría transformar muchas áreas. Por ejemplo, los médicos podrían evaluar mejor a pacientes que parecen inconscientes, y los tratamientos de salud mental podrían mejorar al entender mejor las emociones. También podría cambiar cómo la sociedad trata a los animales y a los sistemas de IA, generando nuevas preguntas éticas. Las ideas legales sobre responsabilidad podrían cambiar.\n\n**Siguiente paso** – Los científicos quieren colaborar más, probando juntos diferentes teorías sobre la conciencia. Este trabajo en equipo ayudará a superar desacuerdos y acelerar el progreso. También quieren estudiar cómo se siente la conciencia, no solo cómo funciona, para preparar a la sociedad para los retos de reconocer o crear conciencia.\n\n**Resumen en una frase** – Entender y probar la conciencia es urgente ante los avances en IA y tecnologías cerebrales, con grandes efectos esperados en medicina, ética, leyes y tecnología.",
      "image_url": "public/images/news_image_Existential-risk-Why-scientists-are-racing-to-defi.png",
      "image_prompt": "A warm, detailed painting of an open human brain gently cradled in glowing hands made of light, with softly pulsing neural networks connecting to abstract, translucent AI circuits and delicate, semi-transparent brain organoids floating nearby, all set against a calm, neutral background of soft earth tones."
    },
    {
      "title": "Developmental convergence and divergence in human stem cell models of autism",
      "summary": "Nature, Published online: 29 January 2026; doi:10.1038/s41586-025-10047-5Risk associated with genetically defined forms of autism spectrum disorder (ASD) can propagate by means of transcriptional regulation to affect convergently dysregulated pathways, providing insight into the convergent impact of ASD genetic risk on human neurodevelopment.",
      "content": "Collection and characterization of hiPS cell lines\n\nControl hiPS cell lines in this study were reported and have been extensively characterized using standardized methods44,50,51. hiPS cell lines from 11 idiopathic ASD individuals were obtained from Coriell. The 22q11.2 deletion44, 22q13.3 deletion108 and Timothy syndrome45 hiPS cell lines were reported and characterized before. To confirm the various genetic mutations, whole-genome sequencing was performed. Cultures were regularly tested for mycoplasma and maintained mycoplasma free. Approval for reprogramming and differentiation of these cell lines was obtained from the Stanford Institutional Review Board panel, and informed consent was obtained from all individuals.\n\nReprogramming and hiPS cell culture\n\nHuman fibroblast cells were reprogrammed using the Sendai virus-based CytoTune iPS 2.0 kit (CytoTune 2.0, Invitrogen, A16517). Fibroblasts were plated in six-well plates 2 days before transduction to achieve a density of 2 × 105 to 3 × 105 cells per well. Cells were then transduced with the indicated set of Sendai vectors at a multiplicity of infection of 5–5–3 (KOS–Myc–Klf4) as we previously described in ref. 44. Virus was removed after 24 h and cells were cultured in fibroblast medium with 10% FBS (Gibco, 16000-044) in Dulbecco’s modified Eagle medium (DMEM) (Gibco, 10569-010) for a total of 7 days, with media changes every other day. On day 7 after transduction, cells were collected with TrypLE (Gibco, 16563-029) and plated in the fibroblast medium onto truncated recombinant human vitronectin (VTN-N, Gibco, A14700)-coated plates. The following day, fibroblast medium was changed to Essential 8 medium (Gibco, A1517001) and cells were fed daily until days 20–22. For further culture, individual colonies were manually dissected and transferred to fresh vitronectin-coated dishes. Once hiPS cell clones were established, they were routinely cultured on vitronectin-coated dishes in Essential 8 medium, and cells were split every 4–5 days using 0.5 mM EDTA (Invitrogen, 15575-020). hiPS cell clones and lines were also generated using retroviruses or non-integrating episomal vectors from fibroblasts109. We did not observe any systematic differences between cells reprogrammed by the two methods. hiPS cells were cultured as previously described in ref. 51. Briefly, hiPS cells were cultured on six-well plates coated with recombinant human vitronectin (VTN-N, Gibco, A14700) in Essential 8 medium (Gibco, A1517001) and passaged with 0.5 mM EDTA (Gibco, 15575). To coat the six-well plates, 1 ml of vitronectin (diluted at a 1:100 ratio with Dulbecco’s phosphate-buffered saline (DPBS); Gibco, 14190) was added per well and then incubated at room temperature for 1 h. To passage hiPS cells with 80–90% confluency, cells were rinsed with 3–4 ml of DPBS per well, and then 1 ml of 0.5 mM EDTA (Gibco, 15575) was added and incubated for 7 min at room temperature. After the EDTA was removed, 2 ml of prewarmed complete Essential 8 medium was added to collect cells. The cell suspension was then diluted in Essential 8 medium (1:6–1:20 depending on the hiPS cell line) and distributed on vitronectin-coated wells.\n\nGeneration of hCOs from hiPS cells\n\nFor the generation of 3D spheroids, hiPS cells were incubated with Accutase (Innovate Cell Technologies, AT-104) at 37 °C for 7 min and dissociated into single cells. To obtain uniformly sized spheroids, we used AggreWell 800 plates (STEMCELL Technologies, 34811) containing 300 microwells. There were roughly 3 × 106 single cells per well in Essential 8 medium supplemented with the ROCK inhibitor Y-27632 (10 μM, Selleckchem, S1049), centrifuged at 100g for 3 min to capture the cells in the microwells and incubated at 37 °C with 5% CO 2 . After 24 h, day 0 of differentiation, spheroids were collected from each microwell by firmly pipetting (with a cut end of a P1000 tip) medium in the well up and down, and transferring it into ultra-low-attachment plastic dishes (Corning, 3262) in Essential 6 medium (Gibco, A1516401) supplemented with two SMAD pathway inhibitors: dorsomorphin (2.5 μM, Sigma-Aldrich, P5499) and SB431542 (10 μM, Tocris, 1614) together with Wnt pathway inhibitor XAV939 (1.25 μM, Tocris, 3748). Media changes were performed daily, except for day 1. On the sixth day in suspension, neural spheroids were transferred to neural medium containing Neurobasal-A (Gibco, 10888), B-27 supplement without vitamin A (Gibco, 12587), GlutaMax (1:100, Gibco, 35050) and penicillin and streptomycin (1:100, Gibco, 15140). The neural medium was supplemented with epidermal growth factor (20 ng ml−1, R&D Systems, 236-EG) and basic fibroblast growth factor (20 ng ml−1, R&D Systems, 233-FB) until day 24. From days 25 to 42, to promote differentiation of the neural progenitors into neurons, the neural medium was supplemented with brain-derived neurotrophic factor (20 ng ml−1, Peprotech, 450-02) and neurotrophin 3 (20 ng ml−1, Peprotech, 450-03), with medium changes every other day. From day 43 onwards, only neural medium without growth factors was used for medium changes every 4–5 days.\n\nRNA-seq processing\n\nSequencing libraries were prepared using TruSeq stranded RNA RiboZero Gold (Illumina) on ribosomal RNA-depleted (RiboZero Gold, Illumina) RNA. The libraries were sequenced with 100-base-pair paired-end reads on an Illumina HiSeq 4000. The reads were mapped to the human genome (hg38) with Gencode v.25 annotations using STAR (v.2.5.2b)110 and gene expression was quantified using RSEM (v.1.3.0)111. Genes that were expressed at very low levels (fewer than 10 reads in 30% of samples from a given day) were removed from the analysis. Samples with standardized sample network connectivity Z scores below −2 in each mutation were defined as outliers and removed112. To control for technical variation due to the sequencing and library prep we calculated the principal components of the Picard sequencing metrics (http://broadinstitute.github.io/picard/) using the CollectAlignmentSummaryMetrics, CollectRnaSeqMetrics and MarkDuplicates modules, and included them in our model. To infer genetic ancestry, we called single-nucleotide polymorphisms (SNPs) from the aligned reads using the GATK (v.3.3) Haplotype caller113. Sites with more than 5% missing samples, with rare minor allele frequency (less than 0.05) and Hardy–Weinberg disequilibrium (less than 1 × 10−6) were removed using plink (v.1.09)114. We then used the remaining high-quality SNPs to run MDS together with HapMap3.3 (hg38)115. The first two MDS values, referred to as genetic ancestry principal components 1 and 2 (PC1, PC2), were then included in our model. Sample identity was verified using the identity by descent algorithm from PLINK (v.1.09)114. Identity by descent was calculated for each pair of samples based on genotypes derived from RNA-seq analysis as well as for all pairs of RNA-seq and DNA sequencing samples. Samples with a \\(\\hat{\\pi }\\) < 0.8 from other samples derived from the same individual were removed. Sex was verified for each sample by detection of genes expressed by the Y chromosome.\n\nSample with high levels of duplication (Picard tools, PERCENT_DUPLICATION > 65), high levels of intergenic mapping (Picard tools, PCT_INTERGENIC_BASES > 60) or with low levels of messenger RNA (RNA) (Picard tools, PCT_MRNA_BASES < 0.5) were removed. All RNA-seq samples passing quality control are listed in Supplementary Table 1. Variance partitioning was performed using the variancePartition package (v.1.20.0) with default parameters. Gene-expression reproducibility was measured using Spearman’s correlation between every pair of samples in a given time point and mutation both within and between individuals.\n\nWhole-genome sequencing\n\nLibraries were prepared using TruSeq DNA PCR-Free (Illumina) and were sequenced with 150-base-pair paired-end reads on an Illumina HiSeq 4000. Lines that underwent whole-genome sequencing are in Supplementary Table 2: further lines were quality controlled previously44. Sequencing data were processed as previously described in ref. 8.\n\nThe sequencing reads were mapped to the human genome (hg38) using Burrows–Wheeler Aligner (bwa-mem, v.0.7.17)116. The resulting BAM files were merged using bamtools (v.2.5.1)117 resulting in a single BAM file per sample. Duplicate reads were marked using the Picard MarkDuplicates tool (v.2.5.0). Reads around indels were locally realigned using GATK’s IndelRealigner (v.3.3). Base quality score was recalibrated using GATK113. Variant and non-variant bases in the genome were identified using GATK’s HaplotypeCaller (v.3.3). Resulting variant cal formats were combined using GATK’s combineGVCFs (v.3.3) and variants were called per chromosome using GATK’s GenotypeGVCFs (v.3.3). Well-calibrated quality scores were generated using GATK’s Variant Quality Score Recalibration (v.3.3). Large chromosomal changes, resulting from iPS cell chromosomal instability, were identified using DELLY (v.0.8.7)118. Lines with large indels (more than 750 kb) that were confirmed using allele frequency in the RNA-seq data were removed from the analysis. This included five individuals in whom all lines were dropped (four because of incorrect or absent mutations, one that did not pass quality control). Twenty-six lines in total (19 individuals) were dropped due to quality control failures. These include seven lines that were dropped due to failure to confirm mutation (four individuals), nine lines dropped due to large CNVs (seven individuals), two lines dropped due to leftover Sendai virus (two individuals), four due to further or improper deletions (four individuals) and four that were not fully characterized or did not pass quality control (two individuals). Point mutations in SHANK3, PCDH19 and CACNA1C were visually confirmed using Integrative Genomics Viewer (v.2.9.4)119. Sequencing depth was calculated using Samtools depth command (v.1.9)120. All whole-genome sequencing samples are listed in Supplementary Table 2.\n\nDifferential expression\n\nGene counts were normalized using trimmed mean of M values121 as implemented in the calcNormFactors function from the edgeR package (v.3.26.8)122. The mixed linear model used included differentiation day, sex, batch, the first 2 principal components calculated for genetic ancestry and 15 sequencing principal components (SeqPCs) as fixed effects, and accounted for many samples coming from the same individual, hiPS cell line and differentiation, and for samples that were sequenced several times as random effects. The model was implemented using the dream function from the variancePartition package (v.1.20.0)123. Genes with FDR < 0.05 were considered to be differentially expressed. To conduct meta-analyses on mutational differential gene expression, we used the metafor (v.4.6.0) package by fitting a fixed-effect model with the rma function for each time point124. FDR < 0.05 genes were considered to be differentially expressed. GSEA was run on metafor analysis output to determine enriched pathways using the fgsea package (v.1.3.0).\n\nIndependent component analysis\n\nIndependent component analysis was performed using the JADE algorithm as implemented in the MineICA package (v.1.30.0)125. The number of components was set to 36 with 10,000 maximum iterations. Association of the independent component with the forms of ASD was tested using a mixed linear model. The model was implemented using the lme function from the nlme package (v.3.1.152). Contrasts were used to compare each form of ASD at each time point to the control at the same time point using the glht function from the multcomp package (v.1.4.18). Like other component analyses, independent component directions are random and so enrichment was performed for both positively and negatively contributing genes. Unlike principal components, independent components are not inherently ordered and were therefore ordered by the amount of kurtosis in each independent component.\n\nGSEA\n\nGSEA was performed using the fgsea package (v.1.10.1)126 on all genes with 1,000,000 permutations and a set size ranging from 30 to 500. Gene ontology gene sets (v.7.0) were downloaded from http://software.broadinstitute.org/gsea/msigdb/. For differential expression genes were ranked by log 2 FC and for independent component analysed genes were ranked by the projection values of the genes on each component. Enrichment for high-confidence ASD genes (gene score of two or less, or syndromic genes) from the SFARI database (https://gene.sfari.org/database/gene-scoring/), from large scale ASD sequencing studies2,8, and risk genes for NDDs, intellectual disability and brain disorders91 was performed using Fisher’s exact test.\n\nNetwork analysis\n\nGene counts were normalized using conditional quantile normalization (v.1.36.0)127 and the covariates sex, tissue of origin, genetic ancestry PC1 and PC2 and the first 15 technical sequencing principal components were regressed out. The network was constructed using the WGCNA package (v.1.70.3)88 using a signed network for each time point separately. A modified version of robust WGCNA was used to reduce the influence of potential outlier samples on network architecture26. Samples were resampled from within each form of ASD ensuring that each iteration contained at least four samples from each form. In total, 100 networks were constructed followed by consensus network analysis that takes the median of the topological overlap dissimilarity matrix across the 100 networks88. Soft-threshold powers of 13, 9, 13 and 14 were used for days 25, 50, 75 and 100, respectively, to achieve approximate scale-free topology (R2 > 0.8). Modules were constructed using a minimal module size of 160, deep split of 4, cut height for creation of modules of 0.9999 and cut height for merging modules of 0.1. Each module eigengene (first principal component of the module) was tested for association with the different forms of ASD as well as for association with ASD overall using linear models. Module gene-ontology term enrichment was performed using clusterProfiler (v.4.0.5)128 with default parameters. Enrichment for common variation associated with ASD21, schizophrenia129, attention-deficit/hyperactivity disorder130, major depressive disorder131 and bipolar disorder132 was calculated using a stratified LDscore regression (v.1.0.0)133. SNPs with 10 kb of a gene were assigned to that gene and the enrichment was calculated as the proportion of SNP heritability accounted for by the genes in the module divided by the proportion of total SNPs within the module. Cell-type enrichment was performed using the bootstrap enrichment method from the EWCE package (v.1.0.1)134 using control samples from previously published single-cell data from a human cortical spheroids set44 with 100,000 permutations. As the background gene set, all genes expressed in both the current dataset and the single-cell dataset were used. Enrichment for high-confidence ASD genes (gene score of two or less or syndromic genes) from the SFARI database (https://gene.sfari.org/database/gene-scoring/) and ASD postmortem modules14 was performed using Fisher’s exact test. Module trajectories were modelled using polynomial splines with two degrees of freedom and two degrees of the piecewise polynomial and tested for significant differences using a linear model. Module preservation was performed using the modulePreservation function from the WGCNA package with 100 permutations. Preservation was tested (1) at other time points within the current data set (2) in cortical samples from early developmental stages (8–16 weeks postconception) from the BrainSpan in vivo data set and (3) in other stem cell-based neuronal models81,82,83,84. To test the association of each ASD form with WGCNA modules, we ran a linear regression comparing the module eigengene of each module by form (as factor variable with control participants as the base level) or by diagnosis (affected versus control) using the lm() function. Adjusted R values of the regression are multiplied by the sign of the sum of model coefficients to determine direction of effect. Estimates for individual forms were derived from the model coefficients. We show FDR-corrected P values in the figures.\n\nClustering stability\n\nThe different conditions (ASD form/differentiation day) were clustered based on the Spearman correlation of log 2 FC of all expressed genes using the Ward.D2 clustering method on Euclidean distances as implemented in the ComplexHeatmap package (v.2.9.3)135. Cluster significance was tested using multiscale bootstrap resampling as implemented in the pvclust function in the pvclust package (v.2.2.0)136 using the Ward.D2 clustering method on Euclidean distances with 10,000 bootstraps. The bootstrap probability measure is the frequency that a cluster appears in the bootstrap replicates. To test for clustering similarity across clustering methods, clustering was performed using the Ward.D, Ward.D2, complete, average and Mcquitty methods on each of the Euclidean, maximum, Manhattan and Minkowski distances. For each pair of clustering and distance methods the cophenetic correlation was measured using the cor.dendlist function from the dendextend package (v.1.14.0)137. Cophenetic correlation is a measure of how well the pair-wise distances of the unmodeled data are preserved in the dendrogram138. In addition, the Rand index was measured for each combination of these pairs using the rand.index function from the fossil package (v.0.4.0)139. Rand index is a measure of the similarity between two trials of clustering using the same data140. To verify that the clusters were not driven by a small subset of genes, we subset the genes used for clustering to 10,000, 5,000 or 2,000 random genes 100 times. The resulting genes were correlated using Spearman correlation and clustered using the Ward.D2 clustering method on the basis of Euclidean distances. Cophenetic correlation and Rand indexes were calculated as above.\n\nDeconvolution\n\nBulk RNA-seq counts were deconvolved using the control cell profiles from previously published single-cell data44 from day 75–85 organoids to deconvolve day 50, 75 and 100 time points, and new single-cell libraries were created with standard 10X methods from day 25 organoids to deconvolve the day 25 time point. Single-cell datasets were processed and integrated separately using standard Seurat v.5 workflows. The reference-based decomposition was performed using the ReferenceBasedDecomposition function from the BisqueRNA package (v.1.0.5)141. Changes in cell-type proportion were tested using a logit mixed linear model. The logit transformation was performed using the logit function from the car package (v.3.0.11) with a 0.001 adjustment. The model was implemented using the lme function from the nlme package (v.3.1.152). Contrasts were used to compare each form of ASD at each time point to the control at the same time point using the glht function from the multicomp package (v.1.4.18).\n\nTranscription factor binding over-representation\n\nTo identify transcription factor binding motifs over-represented in each module we used RcisTarget (v.1.6.0)142. The transcription factor data base used was hg38 and included 10 kb upstream and downstream of the transcription start site (version 9; hg38__refseq-r80__10kb_up_and_down_tss.mc9nr). Only high-confidence annotated transcription factors were used for downstream analysis. The regulatory relationship between modules was calculated as a kME (which is the correlation of each gene in the module with the module eigengene) weighted proportion of the number of genes regulated by the upstream module in the downstream module such that: \\(\\mathrm{score}=\\frac{\\sum k\\mathrm{ME}\\,\\mathrm{of}\\,\\mathrm{regulated}\\,\\mathrm{genes}\\,\\mathrm{in}\\,\\mathrm{the}\\,\\mathrm{module}}{\\mathrm{Total}\\,\\mathrm{number}\\,\\mathrm{of}\\,\\mathrm{genes}\\,\\mathrm{in}\\,\\mathrm{the}\\,\\mathrm{module}}\\). This weighted proportion puts larger weight on genes that are highly connected within the module. A module was considered to be highly regulated by another module if the phosphastaseME weighted score was above 1 standard deviation above the mean (which corresponded to a weighted score of 0.341).\n\nPPIs\n\nPPIs were mapped using the Dapple143 module (v.0.19) in GenePattern (http://genepattern.broadinstitute.org) using the hg19 genome build with 1,000 permutations.\n\nIP–MS\n\nTo validate predicted PPIs, we generated mass spectrometry data from key regulator proteins predicted to form a PPI. We tested antibodies against RELA (Active motif 40916), TP53 (Abcam ab26), CNOT6 (CST no. 13415), TBP (CST no. 8515), POLR2A (PTG 20655-1-AP), SOX9 (CST no. 82630), SMARCB1 (CST no. 91735), SMARCA4 (Abcam ab110641) and EP300 (Abcam ab275378). All antibodies were run at 1:1,000 concentrations. Antibodies that generated western blot bands at the appropriate size were selected for continued mass spectrometry analysis (run once; Fig. 5a). For western blot analysis of the proteins of interest, cell lysates were diluted in 6× SMASH buffer (5 mM Tis HCL pH 6.8, 10% glycerol, 2% SDS, 0.02% bromophenol blue and 1% beta-mercaptoethanol) and boiled for 10 min at 95 °C. Samples were then separated on a NuPAGE 4–12% Bis-Tris Protein Gel (Invitrogen) and transferred to a polyvinyl difluoride membrane (Life Technologies, 100 V, 2 h). Membranes were incubated at room temperature for 1 h in tris-buffered saline with Tween (TBST) (0.1% Tween) with 5% BioRad Blotting-grade Blocker and then incubated overnight with antibodies listed above at 4 °C. After 3× 10-min washes in TBST, blots were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 45 min and again washed three times in TBST. The following secondary antibodies were used: anti-mouse IgG HRP-linked (NA9310V, Sigma-Aldrich) and anti-rabbit IgG HRP-linked (GENA934, Sigma-Aldrich) at a concentration of 1:5,000. Western blots were imaged using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). Western blots were considered successful if the band was visualized at the expected molecular weight (Fig. 5a). For the 6 proteins that showed successful western blots, 1–2 mg of protein extract was incubated with primary antibody (1–2 µg) at 4 °C overnight (1 µg of primary antibody to 1 mg of protein). Following primary antibody incubation 100 µl of Protein A/G beads (Pierce) were added and incubated for 4 h at 4 °C, followed by 1 wash with lysis buffer (Pierce) with added Halt protease and phosphatase inhibitors (Thermo Scientific), 2 washes with PBS and then resuspended in PBS for mass spectrometry.\n\nMass spectrometry and quantification\n\nSamples were processed and quantified for mass spectrometry as in ref. 90 for the 6 proteins (TBP, POLR2A, SOX9, SMARCB1, SMARCA4 and EP300) with a western blot signal in NGN2-derived NPCs at day 4 (refs. 90,144,145). Briefly, NPCs were collected at day 4 following NGN2 expression and dual SMAD/WNT inhibition in the presence of doxycycline (rtTA, tetON-NGN2). Cells were pelleted, washed with PBS and resuspended in 10× packed cell volume immunoprecipitation lysis buffer (Thermo Scientific) with added Halt protease and phosphatase inhibitors (Thermo Scientific) for 20 min at 4 °C. Cells were then centrifuged (16,200g, 20 min, 4 °C and resuspended in 3× packed cell volume. Samples were quantified using the Thermo BCA protein assay. Immunoprecipitations were eluted using SDS and subject to electrophoresis for gel extraction. Bands were excised and cut into roughly 1 mm3 pieces. Gel pieces were then subjected to a modified in-gel trypsin digestion procedure, washed and dehydrated with acetonitrile for 10 min, followed by removal of acetonitrile. Pieces were then completely dried in a speed-vac. Rehydration of the gel pieces was with 50 mM ammonium bicarbonate solution containing 12.5 ng µl−1 modified sequencing-grade trypsin (Promega) at 4 °C. After 45 min, the excess trypsin solution was removed and replaced with 50 mM ammonium bicarbonate solution to just cover the gel pieces. Samples were then placed in a 37 °C room overnight. Peptides were later extracted by removing the ammonium bicarbonate solution, followed by 1 wash with a solution containing 50% acetonitrile and 1% formic acid. The extracts were then dried in a speed-vacuum (roughly 1 h). The samples were then stored at 4 °C until analysis.\n\nOn the day of analysis, the samples were reconstituted in 5–10 µl of high-performance liquid chromatography solvent A (2.5% acetonitrile, 0.1% formic acid). A nano-scale reverse-phase high-performance liquid chromatography capillary column was created by packing 2.6-µm C18 spherical silica beads into a fused silica capillary (100 µm inner diameter by roughly 30 cm in length) with a flame-drawn tip. After equilibrating the column each sample was loaded by using a Famos auto sampler (LC Packings) onto the column. A gradient was formed, and peptides were eluted with increasing concentrations of solvent B (97.5% acetonitrile, 0.1% formic acid). As peptides eluted, they were subjected to electrospray ionization and then entered an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific). Peptides were detected, isolated and fragmented to produce a tandem mass spectrum of specific fragment ions for each peptide. For all IP–MS experiments, the following isotype control antibodies were used: rabbit IgG monoclonal (EPR25A) (Abcam, no. ab172730), rabbit IgG polyclonal (Abcam, no. ab37415) and mouse IgG1 κ monoclonal [MOPC-21] (Abcam, no. ab18443). Mass spectrometry experiments that yielded significance for the protein bait over IgG control samples were then included in analyses (all proteins except SOX9).\n\nPeptide sequences (and hence protein identity) were determined by matching the UniProt human protein database (release 2023_01) with the acquired fragmentation pattern using Sequest (Thermo Fisher Scientific)146. The database included a reversed version of all the sequences and the data were filtered to between 1% and 2% peptide FDR. Protein quantification was performed using GFY Core Version 3.8 (Harvard University). IP–MS data analysis is described in ref. 90.\n\nPPI analyses\n\nTo determine whether the M5 proteins formed a significant interaction network, we compared the logFCs between each ‘bait’ and the other interactors predicted to be in the M5 network and found as a protein in any of the mass spectrometry experiments (943 unique proteins identified across all IP–MS experiments). If the interactors were not pulled down by the bait, the logFC was considered 0. We used the mean logFC across baits as a measure of average connectedness of the network. To assess the statistical significance of these networks, we ran 10,000 permutations by randomly selecting proteins of the same size as the network from the remaining set of 943 uniquely identified proteins. We compared the average logFC of each of these randomly generated networks to create a population curve. We then examined the z-scored connectedness of the network. Gene lists used to compare networks were SFARI genes (levels 1, 2, S), ASD risk genes2,8, intellectual disability risk genes91, NDD risk genes91 and developmental disorder enriched, ASD enriched and NDD non-specific92.\n\ngRNA design and CROP-seq cloning\n\nThree genomic RNAs (gRNAs) per target as well as 18 total non-targeting controls (NTC) were designed using the CRISPick database (https://portals.broadinstitute.org/gppx/crispick/public) (Supplementary Table 15). NTCs were both gRNAs with no sequence in the human genome as well as gRNAs targeting random intergenic sequences. Sequences were designed as follows: a 5′ overhang (ATCTTGTGGAAAGGACGAAACACC) and a 3′ overhang (GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGT) that is compatible with the CRISPR droplet sequencing (CROP-seq) vector were added on the outside of the gRNA sequence. A G nucleotide was also incorporated between the 5′ overhang and the gRNA sequence. All oligos were ordered as a pool (Integrated DNA Technologies). The CROP-seq-opti-dsRed vector backbone was obtained from Addgene (Addgene no. 201999) and digested using New England Biolabs’ (NEB) BsmBI enzyme. The oligo pool was diluted at a concentration of 100 µM, PCR amplified, (Q5 Hot Start High-Fidelity 2X Master Mix) gel extracted, and cleaned. The vector and the pooled oligo insert was then assembled (NEBuilder HiFi DNA Assembly Reaction). To validate the insertion was present post assembly, a PCR amplification using the U6 outer forward primer (TTTCCCATGATTCCTTCATATTTGC) and gRNA end reverse primer (AGTACAAGCAAAAAGCAGTGTCTCAA) was run and visualized. All gRNA sequences used for M5 targets and control samples are supplied in Supplementary Tables 14 (targets) and 15 (control samples). The pooled vectors were then transformed into NEB Stable Competent E. coli (High Efficiency), and plated at various dilutions on Luria-Bertani medium:ampicillin 1:1,000 plates overnight at 30 °C. Colonies were picked and PCR amplification of the insert was done to insure its presence. All bacterial colonies were then scraped from the plate and grown using 200 ml of 2.5% Luria-Bertani medium + 1:1,000 ampicillin. The broth containing colonies was then shaken at 170 rpm at 30 °C and this was complete once the optical density reached 2.0 nm. DNA was then isolated by use of the Qiagen Maxi Plasmid Kit.\n\nLentiviral production\n\nHuman embryonic kidney 293T (HEK293T) cells obtained from American Type Culture Collection (lines CRL-3216 and TIB-202) were expanded in DMEM, 10% FBS and 1% penicillin and streptomycin (HEK medium). Then 5 × 106 HEK293T were plated onto each of 2 poly-ornithine (5 µg ml−1) coated 10-cm plates for 24 h. Media from both plates was replaced with Opti-MEM before cells from 1 10-cm plate were transduced with a lentiviral vector (pLV-KRAB-dCas9 (Addgene no. 71236) or CROP-seq-opti-dsRed (Addgene no. 201999)) while the other plate of cells was transfected with 15 µg of the pooled plasmid library, 15 µg of psPAX2 and 1.5 µg of VSV-G with lipofectamine 3000 following the manufacturer’s instructions. After 16 h, the Opti-MEM media was replaced with 10 ml of HEK medium, which was collected and replaced every 24 h twice. The HEK medium was then spun down with 12.5 ml of lenti-X concentrator (Takara Bio) and centrifuged at 1,500g for 45 min. The supernatant was discarded and the pellet was resuspended in 400 µl of PBS, aliquoted and stored at −80 °C.\n\nDerivation of NGN2-induced neural cells, transduction and FACS\n\nWe derived NGN2-induced hNPCs according to ref. 100. A six-well plate was coated with Matrigel (1:50 in Knockout DMEM) for 2 h at 37 °C. A dox-inducible NGN2 iPS cell line, WTC11 (from L. Gan, Weill Cornell, available at Coriell), was seeded at 75,000 cells per cm2 in MTeSR+ supplemented with 10 µM of Y-27632. After 24 h, cells were subjected to induction medium (1:100 glutamax, 1:66.7 20% glucose in DMEM:F12, N2 supplement 1:100, doxycycline 2 µg ml−1, LDN-193189 200 nM, SB431542 10 µM, XAV939 2 µM). Day 2 involved the induction and selection using the following media: 1:100 glutamax, 1:66.7 20% glucose in DMEM:F12, N2 supplement 1:100, doxycycline 2 µg ml−1, LDN-193189 100 nM, SB431542 5 µM, XAV939 1 µM and puromycin 5 µg ml−1. Then 24 h postselection, the media was changed fully with NES complete and selection media (DMEM:F12, glutamax 1:50, penicillin and streptomycin 1:100, MEM NEAA 1:100, B-27 without vitamin A 1:50, N2 supplement 1:100, epidermal growth factor 10 ng ml−1, basic fibroblast growth factor 10 ng ml−1, puromycin 5 µg ml−1 and Y-27632 1:1,000). One day later and for the duration of the culture, cells were put on NES complete medium, which is the same as listed above apart from the use of Y-27632 and puromycin. Once hNPCs were generated, 500,000 hNPCs were seeded in every well of a six-well plate with NPC maintenance media (n = 6 replicates). To each well, GFP-KRAB-dCas9 (40 µl per well of a six-well plate) plasmid and CROP-dsRed-gRNA (33 µl per well of a six-well plate) were added. Media was replaced daily for 7 days before cells were collected for fluorescence-activated cell sorting (FACS). FACS was done with BD FACSAria, Software FACS Diva v.8.0.2. For FACS, hNPCs were washed with PBS, dissociated into single-cell suspension using Accutase and resuspended in 500 µl of FACS buffer per replicate (7.5% BSA, 0.5 M EDTA, RNase inhibitor 1:200, DAPI 0.5 mg ml−1). A population of NPCs that were not transfected with plasmid were used as a negative control to establish FACS gating. Double positive GFP/TdTomato (dCAS9–single-guide RNA double expressing) cells were sorted for downstream single-cell analyses (roughly 30,000 cells per replicate after FACS, roughly 20% of live cell fraction).\n\nscRNA-seq\n\nSorted cells then underwent scRNA extraction using the 10X genomics Chromium Next GEM Single Cell 3′ GEM, Library & Gel Bead Kit v.3.1 (PN-1000121). The 10X protocol for library prep was adapted from ref. 147. gRNA libraries were sequenced separately from scRNA (GEX) libraries. scRNA and gRNA libraries were aligned to the human genome (GRCh38) with CellRanger (v.7.0.1). Roughly 10,000 aligned cells were recovered per replicate. Cells were filtered to include cells with more than 200 features and percentage of mitochondria less than 10%. Doublets were then removed using DoubletFinder (8,406 doublets, 13.2%). After quality control and doublet filtering before selecting uniquely gRNA positive cells, the median nCounts per cell was 17,071 and the median nGenes was 4,675, from 55,216 singlets (Extended Data Fig. 13c). Single-cell data were then processed using standard best practices for Seurat v.5. Briefly, we log-normalized counts and performed integration using SCTransform followed by clustering. Canonical markers were used to determine cell-type classification including NPC markers SOX2, NES, VIM and HES1 and cNPCs expressing G2 mitotic markers TOP2A, HMGB2, CDK1 and NUSAP1 (Extended Data Fig. 13e). We then assigned gRNAs to cells and filtered cells as follows. BAM files generated from gRNA libraries were analysed as in ref. 148 (GitHub, https://github.com/shendurelab/single-cell-ko-screens). In short, a text file of gRNA sequences was supplied as well as the common sequence appearing before the gRNA sequence, and each of these reads was counted from the BAM file and paired to the cells within the scRNA libraries through cell unique molecular identifier matching. Only cells containing gRNA barcodes with a unique molecular identifier count of at least ten were kept in the downstream analysis (Extended Data Fig. 13d). This left a total of 23,672 high-quality singlet cells that had 1 and only 1 gRNA-target assigned (Extended Data Fig. 13d,f). This cut-off has also been previously used148 and was determined to be sufficient for significant decrease in expression of the target. All differential analysis was performed on cells that expressed the gRNA of a single target. A standard pseudobulk differential expression using the edgeR (v.3.40.2) Quasi-Likelihood F test was performed using the libra package (v.1.0.0) function, run_de(). All differential gene expression compared all cells expressing any control gRNAs with all cells expressing any target gRNAs, above the unique 10 unique-molecular-identifier cut-off (3,163 total cells considered as control cells). The range of cells containing each gene target was 171–2,423, median 775. The proportion of cells containing each unique barcode (summarized by gene target) per replicate is shown in Extended Data Fig. 13g. Each replicate sample, taken from different plate wells was considered one sample for psuedobulking.\n\nInclusion and ethics\n\nWe have complied with all ethics guidelines and regulations in conducting this research. Informed consent was obtained from all individuals. Participants were recruited at Stanford University, UCLA, NIMH. Ethics oversight is conducted by Stanford University, UCLA and NIMH.\n\nReporting summary\n\nFurther information on research design is available in the Nature Portfolio Reporting Summary linked to this article.",
      "url": "https://www.nature.com/articles/s41586-025-10047-5",
      "source": "Nature",
      "published": "2026-02-02",
      "sentiment_score": 0.85,
      "reasoning": "The article reports a significant scientific advancement in understanding autism spectrum disorder (ASD) through the use of human induced pluripotent stem cell (hiPS) models, whole-genome sequencing, and transcriptomic analyses. This research provides meaningful insights into the genetic and neurodevelopmental mechanisms underlying ASD, which has broad implications for improving diagnosis, treatment, and potentially prevention of ASD, benefiting a large segment of the population. The article is focused, detailed, and describes a substantial breakthrough in biomedical research with tangible societal impact.",
      "category": "Health",
      "personality_title": "New stem cell study reveals how genetic risks shape brain development in autism",
      "personality_presentation": "**Context** – Autism spectrum disorder (ASD) is a condition that affects how the brain develops and functions. Scientists want to understand how different genetic risks cause changes in brain cells during early development.\n\n**What happened** – Researchers used human induced pluripotent stem cells (hiPS cells), which are special cells made from adult cells that can turn into brain cells. They studied stem cells from people with different forms of genetically linked ASD and compared them to cells from people without ASD. Using advanced methods like whole-genome sequencing and RNA analysis, they tracked how genes were turned on or off during the growth of brain-like structures called organoids.\n\n**Impact** – The study showed that despite different genetic causes, many forms of autism affect similar biological pathways in brain development. This helps scientists understand how diverse genetic risks can lead to common problems in brain cells. These findings bring us closer to better ways to diagnose and treat autism by targeting these shared pathways.\n\n**What's next step** – Scientists plan to use this stem cell model to test new treatments that might correct the gene activity problems found in ASD. They also want to study more genetic types of autism and see how early brain development changes over time.\n\n**One-sentence takeaway** – By studying brain cells grown from stem cells, researchers uncovered shared genetic effects in autism that could guide future diagnosis and therapies.",
      "personality_title_fr": "Nouvelle étude sur les cellules souches révèle comment les risques génétiques influencent le développement cérébral dans l'autisme",
      "personality_presentation_fr": "**Contexte** – Le trouble du spectre autistique (TSA) affecte le développement et le fonctionnement du cerveau. Les scientifiques cherchent à comprendre comment les risques génétiques modifient les cellules cérébrales pendant le développement.\n\n**Ce qui s'est passé** – Des chercheurs ont utilisé des cellules souches pluripotentes induites humaines (hiPS), des cellules spéciales issues de cellules adultes capables de se transformer en cellules cérébrales. Ils ont étudié ces cellules provenant de personnes avec différentes formes génétiques d'autisme et les ont comparées à celles de personnes sans autisme. Grâce à des techniques avancées comme le séquençage du génome complet et l'analyse de l'ARN, ils ont observé l'activité des gènes pendant la croissance de structures cérébrales en laboratoire appelées organoïdes.\n\n**Impact** – L'étude a montré que, malgré des causes génétiques différentes, plusieurs formes d'autisme affectent des voies biologiques similaires dans le développement du cerveau. Cela aide à comprendre comment des risques génétiques variés peuvent entraîner des problèmes communs dans les cellules cérébrales. Ces résultats rapprochent la recherche de meilleurs diagnostics et traitements ciblant ces voies communes.\n\n**Prochaine étape** – Les scientifiques veulent utiliser ce modèle de cellules souches pour tester de nouveaux traitements capables de corriger les anomalies d'activité génétique observées dans le TSA. Ils souhaitent aussi étudier d'autres types génétiques d'autisme et suivre les changements du développement cérébral au fil du temps.\n\n**Résumé en une phrase** – En étudiant des cellules cérébrales issues de cellules souches, les chercheurs ont découvert des effets génétiques communs dans l'autisme, pouvant guider les futurs diagnostics et thérapies.",
      "personality_title_es": "Nuevo estudio con células madre revela cómo los riesgos genéticos afectan el desarrollo cerebral en el autismo",
      "personality_presentation_es": "**Contexto** – El trastorno del espectro autista (TEA) afecta el desarrollo y funcionamiento del cerebro. Los científicos quieren entender cómo los riesgos genéticos causan cambios en las células cerebrales durante el desarrollo temprano.\n\n**Qué pasó** – Investigadores usaron células madre pluripotentes inducidas humanas (hiPS), que son células especiales hechas de células adultas que pueden convertirse en células cerebrales. Estudiaron células de personas con diferentes formas genéticas de TEA y las compararon con células de personas sin TEA. Usaron métodos avanzados como secuenciación del genoma completo y análisis de ARN para seguir cómo los genes se activan o desactivan durante el crecimiento de estructuras similares al cerebro llamadas organoides.\n\n**Impacto** – El estudio mostró que, a pesar de las diferentes causas genéticas, muchas formas de autismo afectan vías biológicas similares en el desarrollo del cerebro. Esto ayuda a entender cómo riesgos genéticos diversos pueden provocar problemas comunes en las células cerebrales. Estos hallazgos acercan a la ciencia a mejores formas de diagnosticar y tratar el autismo al enfocarse en estas vías compartidas.\n\n**Próximo paso** – Los científicos planean usar este modelo de células madre para probar nuevos tratamientos que puedan corregir los problemas de actividad genética encontrados en el TEA. También quieren estudiar más tipos genéticos de autismo y cómo cambia el desarrollo cerebral temprano con el tiempo.\n\n**Resumen en una frase** – Al estudiar células cerebrales cultivadas a partir de células madre, los investigadores descubrieron efectos genéticos compartidos en el autismo que podrían guiar futuros diagnósticos y terapias.",
      "image_url": "public/images/news_image_Developmental-convergence-and-divergence-in-human-.png",
      "image_prompt": "A detailed, warm-toned painting of a glowing, intricate network of interconnected, stylized human stem cells forming a delicate three-dimensional spherical structure, symbolizing brain organoids, surrounded by softly swirling strands of DNA and abstract representations of genetic sequences, all rendered in natural, muted colors with a harmonious and hopeful atmosphere."
    }
  ]
}